Search
Showing results for "early lung health"
We have all heard of the phrase ‘it takes a village to raise a child’ but unfortunately in contemporary western society that ‘village’ can be hard to find.
Medulloblastoma is the most common childhood brain cancer. Mainstay treatments of radiation and chemotherapy have not changed in decades and new treatment approaches are crucial for the improvement of clinical outcomes. To date, immunotherapies for medulloblastoma have been unsuccessful, and studies investigating the immune microenvironment of the disease and the impact of current therapies are limited.
Medulloblastoma is the most common malignant childhood brain tumor, and 5-year overall survival rates are as low as 40% depending on molecular subtype, with new therapies critically important. As radiotherapy and chemotherapy act through the induction of DNA damage, the sensitization of cancer cells through the inhibition of DNA damage repair pathways is a potential therapeutic strategy.
We discovered a previously unknown major resistance mechanism in glioma in that most EGFR domain III-targeting antibodies do not neutralize EGFRvIII
Despite low ERBB4 mRNA in glioblastoma, the functional effects of increased ERBB4 activation identify ERBB4 as a potential prognostic and therapeutic target
The functional effects of increased ERBB4 activation identify ERBB4 as a potential prognostic and therapeutic target
Here we describe a method by which serial biopsy can be used to validate response to dacomitinib treatment in vivo using a mouse glioblastoma model
Medulloblastoma, the most common pediatric malignant brain tumor, consists of at least four distinct molecular subgroups.
Professor Donna Cross and her team at The Kids Research Institute Australia have challenged and overturned damaging attitudes that saw bullying tolerated in childhood.
Here we recognise donors who have made cumulative gifts of $10,000 and above to contribute to children's health research at The Kids Research Institute Australia.